treatment
immunemedi
inflammatori
diseas
improv
consider
last
year
advent
biolog
therapeut
first
cytokin
fulli
valid
therapeut
target
ra
inhibitor
tnfi
revolution
treatment
ra
use
million
patient
worldwid
despit
good
clinic
respons
observ
mani
patient
blockad
offer
cur
treatment
approxim
onethird
patient
respond
loss
efficaci
frequent
observ
importantli
current
possibl
predict
patient
respond
tnfi
therapi
addit
inflammatori
diseas
syndrom
multipl
sclerosi
tnfi
shown
clinic
efficaci
furthermor
paradox
patient
treat
tnfi
develop
de
novo
autoimmun
diseas
observ
indic
underli
mechan
relat
tnf
blockad
human
incomplet
understood
requir
explor
effect
tnfi
widerang
simpli
neutral
biolog
activ
solubl
membranebound
exampl
bind
antitnf
mab
mediat
cell
death
complementdepend
cytotox
antibodydepend
cellular
cytotox
inhibitor
also
shown
affect
downstream
cytokin
pathway
modul
apc
function
promot
regulatori
cell
treg
expans
although
opposit
find
regard
latter
report
recent
data
laboratori
demonstr
tnf
blockad
promot
express
human
cell
shown
crosssect
longitudin
inflammatori
arthriti
patient
tnfi
therapi
increas
frequenc
peripher
blood
pb
cell
vivo
find
reproduc
vitro
cocultur
cell
healthi
donor
autolog
monocyt
mab
presenc
differ
tnfi
drug
adalimumab
infliximab
etanercept
certolizumab
furthermor
show
increas
percentag
coexpress
cell
suggest
otherwis
proinflammatori
cell
display
antiinflammatori
potenti
inde
resort
tnfiexpos
cell
secret
increas
level
biolog
activ
could
modul
marker
monocyt
activ
although
cell
recogn
import
cell
popul
inflammatori
diseas
cell
subset
also
contribut
inflamm
well
cell
also
potent
produc
proinflammatori
cytokin
studi
therefor
investig
vitro
whether
tnf
blockad
regul
express
proinflammatori
cytokineproduc
cell
subset
whether
blockad
cytokin
cell
activ
pathway
also
drive
express
tnf
blockad
may
manifest
effect
cell
peripher
blood
sampl
obtain
healthi
adult
volunt
peripher
blood
mononuclear
cell
pbmc
isol
densiti
gradient
centrifug
use
axisshield
oslo
norway
monocyt
cell
isol
magneticactiv
cell
sort
mac
accord
manufactur
instruct
miltenyi
biotec
bergischgladbach
germani
puriti
confirm
flow
cytometri
monocyt
averag
puriti
isol
posit
select
use
microbead
cell
isol
via
neg
deplet
averag
puriti
experi
cell
subsequ
enrich
posit
select
use
microbead
averag
puriti
experi
cell
sort
high
puriti
part
cell
deplet
treg
facssort
label
cell
percp
pe
alexa
fluor
mab
biolegend
cambridg
uk
studi
approv
bromley
research
ethic
committe
written
inform
consent
obtain
particip
cell
cultur
cultur
medium
rpmi
medium
supplement
heatinactiv
fetal
bovin
serum
lot
south
american
origin
penicillin
streptomycin
lglutamin
life
technolog
carlsbad
ca
usa
freshli
isol
bulk
memori
enrich
cell
monocyt
unless
otherwis
indic
cocultur
ngml
mab
clone
janssencilag
ltd
high
wycomb
uk
cocultur
incub
day
experi
macsisol
cell
cultur
alon
stimul
coat
onto
cultur
plate
pb
minimum
h
well
wash
three
time
pb
ad
cell
cultur
medium
clone
bd
bioscienc
ad
well
final
concentr
experi
whole
pbmc
cultur
ngml
mab
day
indic
follow
recombin
cytokin
neutral
antibodi
reagent
r
system
unless
otherwis
indic
ad
start
cultur
period
recombin
human
rh
ngml
biosourc
camarillo
ca
usa
ngml
ngml
use
gener
data
figur
supplementari
materi
peprotech
rocki
hill
nj
usa
neutralizingblock
antibodi
clone
clone
polyclon
clone
clone
polyclon
follow
isotyp
control
antibodi
use
assayappropri
concentr
human
abcam
cambridg
uk
mous
mous
mous
goat
igg
r
system
clinic
grade
biolog
purchas
via
guy
hospit
pharmaci
adalimumab
abbott
laboratori
chicago
il
usa
frozen
aliquot
use
final
concentr
unless
otherwis
indic
tocilizumab
roch
welwyn
garden
citi
uk
use
abatacept
bristolmy
squibb
new
york
ny
usa
use
pediacel
diphtheria
tetanu
pertussi
acellular
compon
poliomyel
inactiv
haemophilu
type
b
conjug
vaccin
revaxi
diphtheria
tetanu
poliomyel
inactiv
vaccin
gift
jame
read
tim
tree
lab
king
colleg
london
ad
dilut
assess
intracellular
cytokin
express
cell
cultur
cell
restimul
h
presenc
phorbol
pma
ngml
sigmaaldrich
ionomycin
ngml
sigmaaldrich
golgistop
accord
manufactur
instruct
bd
bioscienc
experi
cell
label
fixabl
viabil
dye
ebiosci
san
diego
ca
usa
livedead
fixabl
dead
cell
stain
thermofish
scientif
accord
manufactur
instruct
cell
cocultur
surfac
stain
use
biolegend
apc
miltenyi
biotec
experi
pacif
blue
fix
paraformaldehyd
merck
co
inc
kenilworth
nj
usa
cell
wash
permeabil
saponin
sigmaaldrich
intracellularli
stain
variou
combin
follow
fluoresc
conjug
antibodi
biolegend
pe
percp
pacif
blue
alexa
fluor
pe
percp
pacif
blue
apc
apc
gmcsf
apc
antibodi
detect
andor
ad
intracellularli
allow
stain
marker
follow
cell
cultur
condit
stain
cell
acquir
use
facscantoii
lsrfortessa
bd
bioscienc
experi
cell
event
record
gate
strategi
use
analyz
intracellular
cytokin
express
cell
describ
figur
supplementari
materi
flow
cytometri
data
analyz
use
flowjo
softwar
version
tree
star
inc
ashland
usa
measur
cell
cultur
supernat
use
elisa
max
kit
biolegend
accord
manufactur
instruct
measur
cell
cultur
supernat
use
duoset
human
elisa
ebiosci
accord
manufactur
instruct
microwel
absorb
read
nm
use
wallac
micropl
reader
perkin
elmer
waltham
usa
concentr
analyt
determin
base
standard
curv
includ
plate
statist
test
perform
graphpad
prism
graphpad
san
diego
ca
usa
data
set
test
normal
use
agostino
pearson
omnibu
normal
test
follow
statist
signific
test
use
appropri
test
indic
figur
legend
data
set
n
valu
test
nonparametr
p
valu
consid
statist
signific
investig
whether
tnf
blockad
regul
express
differ
proinflammatori
cytokineproduc
cell
isol
cell
pb
healthi
donor
cocultur
cell
monocyt
mab
ngml
absenc
presenc
antitnf
mab
adalimumab
previous
describ
day
cell
restimul
pma
ionomycin
presenc
golgistop
h
stain
cytokin
express
gate
strategi
shown
figur
supplementari
materi
agreement
previou
data
tnf
blockad
led
signific
increas
cell
within
total
cell
well
cell
subset
addit
found
strong
increas
cell
within
gmcsf
cell
popul
figur
b
tnf
blockad
alter
frequenc
gmcsf
cell
popul
induc
modest
increas
cell
previous
shown
donor
frequenc
although
reach
statist
signific
figur
b
supplementari
materi
addit
isotyp
control
human
mab
promot
express
cell
figur
supplementari
materi
contrari
effect
tnf
blockad
addit
cocultur
cell
monocyt
mab
led
strike
decreas
percentag
cell
within
total
cell
within
cell
subset
gmcsf
cell
test
figur
addit
significantli
alter
frequenc
cell
subset
figur
supplementari
materi
sinc
proinflammatori
cytokineexpress
cell
also
contribut
immunemedi
inflammatori
diseas
investig
whether
tnf
blockad
regul
express
cell
adapt
cultur
system
stimul
whole
pbmc
mab
ngml
absenc
presenc
dose
rang
adalimumab
day
cultur
restimul
pmaionomycin
presenc
golgistop
cytokin
express
assess
within
either
cell
popul
signific
increas
percentag
cell
within
cell
popul
observ
includ
subpopul
figur
regul
express
tnf
blockad
dose
respons
cell
subset
significantli
increas
frequenc
follow
cultur
either
adalimumab
figur
dose
reflect
clinic
effect
trough
level
adalimumab
human
serum
follow
treatment
agreement
data
cellmonocyt
cocultur
addit
ngml
pbmc
led
reduct
cell
frequenc
cell
n
data
shown
sinc
vitro
studi
cell
respons
tnf
blockad
reli
monoclon
stimul
test
whether
tnf
blockad
could
still
elicit
increas
cell
respons
context
physiolog
antigen
stimul
pediacel
pentaval
vaccin
consist
purifi
diphtheria
toxoid
purifi
tetanu
toxoid
acellular
pertussi
vaccin
inactiv
polioviru
haemophilu
influenza
type
b
polysaccharid
revaxi
booster
vaccin
contain
purifi
diphtheria
tetanu
toxoid
inactiv
polioviru
vaccin
ad
cellmonocyt
cocultur
dilut
presenc
absenc
tnf
blockad
day
antigenstimul
cell
cultur
presenc
adalimumab
demonstr
elev
frequenc
compar
cell
expos
tnf
blockad
figur
supplementari
materi
togeth
data
demonstr
vitro
tnf
blockad
provid
physiolog
concentr
physiolog
setup
promot
express
cell
includ
subset
express
proinflammatori
cytokin
thu
far
assess
cytokin
express
follow
vitro
tnf
blockad
carri
day
cultur
time
cours
experi
perform
assess
kinet
express
cell
pbmc
cultur
mab
absenc
presenc
adalimumab
frequenc
express
cell
analyz
h
stimul
data
show
earli
tcr
stimul
h
frequenc
express
cell
within
cell
increas
rapidli
irrespect
presenc
tnf
blockad
howev
later
time
point
h
higher
frequenc
cell
sustain
within
cell
presenc
tnf
blockad
figur
experi
suggest
tnf
blockad
maintain
rather
directli
induc
phenotyp
cell
follow
tcr
stimul
previou
work
demonstr
addit
adalimumab
inhibitor
etanercept
infliximab
certolizumab
well
block
mab
capabl
increas
frequenc
cell
investig
whether
blockad
addit
proinflammatori
pathway
could
promot
express
cell
blockad
enhanc
frequenc
cell
cell
popul
test
figur
blockad
affect
percentag
cell
within
total
cell
within
subpopul
led
modestli
increas
frequenc
express
cell
within
popul
although
effect
much
weaker
effect
tnf
blockad
parallel
cultur
figur
addit
tocilizumab
blockad
abatacept
block
costimul
biolog
drug
routin
use
clinic
treat
rheumatoid
arthriti
increas
frequenc
cell
cell
subpopul
figur
determin
whether
blockad
pathway
might
regul
express
differ
kinet
tnf
blockad
frequenc
analyz
within
cell
differ
time
point
pbmc
cultur
expos
antibodi
drug
cell
frequenc
regul
time
point
blockad
costimul
figur
supplementari
materi
blockad
cellmonocyt
cocultur
result
significantli
increas
proport
cell
within
total
cell
within
subpopul
figur
howev
effect
replic
either
cell
whole
pbmc
cultur
figur
supplementari
materi
indic
capac
blockad
regul
express
may
depend
vitro
cultur
condit
togeth
data
indic
express
cell
cell
regul
block
signal
block
costimul
least
vitro
sinc
monocyt
major
produc
explor
whether
presenc
monocyt
requir
effect
tnf
blockad
regul
cell
sort
high
puriti
stimul
platebound
solubl
mab
absenc
monocyt
place
cocultur
monocyt
mab
without
addit
antitnf
mab
cell
cultur
tnf
blockad
still
brought
increas
cell
frequenc
within
total
popul
also
within
subpopul
similar
increas
frequenc
observ
cellmonocyt
cocultur
figur
b
analysi
supernat
cell
elisa
confirm
level
secret
increas
cultur
presenc
tnf
blockad
figur
one
potenti
interpret
observ
increas
frequenc
cell
follow
tnf
blockad
could
expans
preexist
popul
treg
previou
work
indic
three
donor
macsdeplet
cell
impair
antitnfmedi
increas
frequenc
within
cell
increas
cell
frequenc
appar
upon
tnf
blockad
investig
macsisol
cell
fac
sort
high
puriti
yield
either
total
cell
effector
cell
teff
deplet
treg
cell
cultur
mab
absenc
monocyt
place
cocultur
monocyt
mab
absenc
presenc
adalimumab
data
show
tnf
blockad
still
result
increas
frequenc
cell
effector
cell
absenc
treg
figur
togeth
data
indic
tnf
blockad
regul
express
directli
effector
cell
requir
presenc
monocyt
treg
support
find
tnf
blockad
exert
effect
cell
absenc
monocyt
find
evid
role
monocytederiv
antiinflammatori
mediat
mediat
express
context
tnf
blockad
demonstr
find
tnf
blockad
induc
secret
enhanc
secret
result
increas
percentag
cell
blockad
impair
increas
cell
frequenc
brought
tnf
blockad
figur
supplementari
materi
final
explor
whether
modul
express
cell
tnf
blockad
depend
signal
neutral
antibodi
ad
cellmonocyt
cocultur
stimul
mab
presenc
absenc
tnf
blockad
intracellular
cytokin
express
assess
day
blockad
signal
absenc
adalimumab
led
significantli
reduc
frequenc
within
total
cell
within
subpopul
figur
adalimumab
block
mab
ad
combin
cocultur
decreas
cell
frequenc
observ
compar
condit
treat
adalimumab
alon
howev
increas
still
observ
compar
blockad
alon
data
suggest
pathway
addit
signal
could
play
role
regul
express
tnf
blockad
inde
test
whether
addit
exogen
ngml
could
drive
express
cellmonocyt
cocultur
found
suffici
increas
cell
frequenc
total
cell
within
subpopul
addit
even
decreas
percentag
cell
total
cell
cell
figur
biolog
activ
recombin
valid
cultur
freshli
isol
monocyt
ngml
h
confirm
addit
result
increas
reduc
hladr
express
flow
cytometri
accord
previou
studi
n
data
shown
next
investig
regul
respons
cell
use
whole
pbmc
cultur
assess
express
time
cours
figur
supplementari
materi
found
earlier
time
point
h
addit
reduc
cell
frequenc
n
p
wilcoxon
matchedpair
sign
rank
test
later
time
point
h
slightli
increas
cell
frequenc
n
p
wilcoxon
matchedpair
sign
rank
test
cell
frequenc
remain
low
throughout
regardless
addit
togeth
data
indic
signal
contribut
part
tnf
blockademedi
regul
express
cell
factor
also
play
role
effect
exogen
regul
express
cell
appear
depend
time
vitro
cultur
condit
show
cell
stimul
presenc
tnf
blockad
maintain
proport
cell
express
antiinflammatori
cytokin
phenomenon
observ
total
cell
well
within
varieti
proinflammatori
cytokineexpress
gmcsf
subpopul
tnf
blockad
regul
express
whether
cell
stimul
presenc
absenc
monocyt
antigen
stimulu
use
place
monoclon
stimul
found
blockad
costimul
regul
express
cell
subpopul
block
antibodi
result
increas
cell
frequenc
ad
cellmonocyt
cocultur
effect
replic
whole
pbmc
cultur
one
explan
could
addit
cell
type
present
pbmc
cultur
produc
respond
neither
treg
requir
tnf
blockad
exert
effect
data
confirm
extend
previou
work
show
tnf
blockad
promot
express
cell
support
find
literatur
small
studi
ra
patient
found
frequenc
pbmc
increas
follow
treatment
infliximab
howev
three
patient
studi
confirm
cell
subset
express
ebert
later
show
supernat
cultur
either
monocyt
adher
pbmc
cell
nonadher
pbmc
contain
increas
follow
exposur
infliximab
vitro
antiga
et
al
demonstr
increas
percentag
cell
cell
blast
isol
skin
lesion
psoriasi
patient
follow
treatment
etanercept
pb
cell
also
increas
posterior
uveiti
patient
follow
treatment
receptor
fusion
protein
earlier
studi
assess
mous
transgen
cell
human
cell
clone
also
found
tnf
blockad
led
increas
product
cell
cultur
supernat
support
data
bok
et
al
show
blockad
vitro
prime
cell
tolerogen
dc
favor
develop
cell
thu
tnfimedi
regul
cell
indic
grow
number
vitro
ex
vivo
studi
presenc
cell
report
sever
mous
model
infect
includ
acut
influenza
infect
chronic
mycobacterium
tuberculosi
infect
coronavirusinduc
enceph
furthermor
cell
found
patient
hiv
chronic
hepat
c
infect
express
cell
induc
either
alon
combin
dexamethason
howev
best
knowledg
first
report
show
tnf
blockad
regul
express
cell
stimul
product
variou
effector
cell
subset
data
suggest
howev
capac
tnf
blockad
affect
express
cell
depend
agreement
work
human
cell
found
addit
recombin
cell
result
increas
secret
although
strictli
dosedepend
howev
contrast
studi
use
cell
analysi
intracellular
cytokin
express
demonstr
increas
cell
frequenc
day
cultur
possibl
due
differ
kinet
express
bulk
cell
popul
note
although
cellmonocyt
cocultur
blockad
led
reduc
frequenc
presenc
absenc
tnf
blockad
addit
suffici
drive
express
cell
data
line
previou
work
show
necessari
suffici
enhanc
develop
cell
follow
vitro
differenti
presenc
vitamin
plu
dexamethason
howev
ad
whole
pbmc
cultur
slightli
increas
cell
frequenc
day
cultur
indic
regul
express
cell
depend
vitro
cultur
condit
inflammatori
diseas
ra
normal
balanc
immun
regul
disturb
cellderiv
proinflammatori
mediat
contribut
diseas
pathogenesi
uncontrol
manner
studi
indic
potenti
immunoregulatori
phenotyp
broadli
maintain
effector
cell
follow
exposur
tnf
blockad
may
repres
underappreci
mechan
action
wide
use
therapeut
strategi
previous
provid
evid
secret
cell
follow
tnf
blockad
biolog
activ
howev
work
requir
investig
whether
increas
frequenc
across
differ
cell
subpopul
function
relev
context
inflammatori
diseas
addit
insight
underli
molecular
mechan
via
tnf
blockad
maintain
express
could
identifi
potenti
target
novel
therapeut
strategi
cr
ld
vf
design
perform
experi
analyz
interpret
data
lt
conceiv
studi
contribut
experiment
design
interpret
data
cr
lt
wrote
revis
manuscript
author
edit
manuscript
author
declar
research
conduct
absenc
commerci
financi
relationship
could
constru
potenti
conflict
interest
